

31 Aug 2020 |

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

Join us for a quick audio roundup of five useful things to know from *Scrip's* recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around *Scrip's* Five Must-Know Things, in this episode covering major developments in the business week ended 28 August 2020.

Making headlines this time are setbacks in multiple clinical trials, plans for hyperimmune globulin in COVID-19 and a big divestment deal in Japan.

Stories mentioned in this edition:

(Also see "[Third Death In Audentes' XLMTM Gene Therapy Trial](#)" - Scrip, 21 Aug, 2020.)

(Also see "[Novartis Hits Spartalizumab Phase III Setback In Melanoma](#)" - Scrip, 24 Aug, 2020.)

(Also see "[Bristol/Agios AML Drug Idhifa Fails In Phase III](#)" - Scrip, 25 Aug, 2020.)

(Also see "[After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?](#)" - Scrip, 24 Aug, 2020.)

(Also see "[Takeda Confirms \\$2.3bn Deal With Blackstone For Japan Consumer Business](#)" - Scrip, 24 Aug, 2020.)

[Click here to explore this interactive content online](#) ✨